Skip to main content
International Journal of Nanomedicine logoLink to International Journal of Nanomedicine
. 2020 Dec 2;15:9669–9670. doi: 10.2147/IJN.S293705

Efficient Inhibition of Ovarian Cancer by Degradable Nanoparticle-Delivered Survivin T34A Gene [Corrigendum]

PMCID: PMC7719439  PMID: 33299311

Luo L, Du T, Zhang J, et al. Int J Nanomedicine. 2016;11:501—513.

The authors have advised due to an error at the time of figure assembly, Figure 11 on page 510 is incorrect. The correct Figure 11 is shown below.

Figure 11.

Figure 11

Safety and toxicity evaluation of HPEI/hs-T34A formulation.

Notes: (A) The heart, liver, spleen, lung, and kidney in NS, HPEI alone (50 µg), HPEI/EP, HPEI/hs-T34A, or PEI 25K/hs-T34A group were collected and conducted with HE staining, respectively. Scale bar, 50 µm. (B). Body weight changes in NS, HPEI alone (50 µg), HPEI/EP, HPEI/hs-T34A, or PEI 25K/hs-T34A group, respectively.

Abbreviations: HPEI, heparin–polyethyleneimine; PEI 25K, polyethyleneimine (molecular weight 25,000); HPEI/EP, heparin–polyethyleneimine/empty vector plasmid; NS, normal saline; hs, human survivin.

The authors apologize for this error and advise it does not affect the results of the paper.


Articles from International Journal of Nanomedicine are provided here courtesy of Dove Press

RESOURCES